WHO recommends two-dose shingles vaccine for older adults

The World Health Organization (WHO) published a dedicated position paper on herpes zoster vaccination on July 4, 2025. It superseded the organization's 2014 joint paper on chickenpox and shingles vaccines and focused on the recombinant zoster vaccine.

WHO recommends that countries consider a two-dose recombinant zoster vaccine for older adults and people with chronic conditions when shingles is an important public health problem. It sets a minimum interval of two months and asks countries to weigh disease burden, affordability and cost-effectiveness rather than applying one worldwide program.

Shingles develops when varicella-zoster virus, the virus that causes chickenpox, reactivates after remaining dormant in nerve tissue. The US Centers for Disease Control and Prevention (CDC) says postherpetic neuralgia is the most common complication, affecting about 10 percent to 18 percent of people with shingles and becoming more likely with age.

A rash near the eye needs immediate assessment

Vaccination does not treat an active episode of shingles. WHO classifies a shingles rash near the eye as a medical emergency because eye involvement can threaten vision, and it says antiviral treatment works best when started within 72 hours after the rash appears.

Prompt clinical assessment is also warranted for a widespread blistering rash, new vision changes or suspected shingles in someone with weakened immunity. The US CDC says immunocompromised people are more likely to have a severe or generalized rash and complications that can include vision loss, encephalitis and pneumonia.

Age 50 is common, but it is not a universal access rule

WHO does not prescribe one worldwide eligibility age; its 2025 position paper says countries considering a target age from 50 should weigh national disease burden, affordability, cost-effectiveness and program delivery. Public coverage can be narrower than the vaccine's regulatory authorization.

US CDC guidance recommends two doses of recombinant zoster vaccine for adults aged 50 or older and for adults aged 19 or older who are or will be immunodeficient or immunosuppressed because of disease or treatment. The routine US interval is two to six months, although some immunocompromised adults may receive the second dose after one to two months.

In the European Union, the authorization is similar but not identical. The European Medicines Agency (EMA) authorizes the recombinant zoster vaccine it assessed for adults aged 50 or older and adults aged 18 or older who have an increased risk of shingles. Authorization does not decide whether a national health system pays for the vaccine or which groups it invites.

The current evidence centers on a recombinant vaccine

Recombinant zoster vaccine (RZV) does not contain live varicella-zoster virus. It contains a viral surface protein and an adjuvant that strengthens the immune response, according to the EMA product assessment.

The standard course uses two intramuscular injections. WHO specifies at least two months between doses, while the EU product information and US schedule allow a second dose within two to six months for most adults. The locally approved label and national schedule determine the interval in any particular country.

The older live-attenuated zoster vaccine is not a universal alternative. The US CDC says the live product has not been available in the United States since November 18, 2020, and regulatory status differs elsewhere. A fixed comparison between two products would therefore misstate the choices available to many readers.

Trial results were strong, but they were not identical across groups

In one EMA-reviewed trial, six of 7,695 adults who received recombinant vaccine developed shingles, compared with 210 of 7,710 placebo recipients over a little more than three years on average. The agency calculated 97 percent efficacy against shingles in that study.

A pooled analysis of adults aged 70 or older from two trials found 25 shingles cases among 8,250 vaccine recipients and 284 among 8,346 placebo recipients within four years. The corresponding estimates were 91 percent efficacy against shingles and 89 percent against postherpetic neuralgia.

Results in immunocompromised groups varied. The EMA reports estimated efficacy of 68 percent in a study of people who had received an autologous stem-cell transplant and 87 percent in a study of people with blood cancer. Those findings do not establish the same level of protection for every disease, treatment or immune state.

Prior shingles and a late second dose do not always reset the plan

Under US CDC guidance, a previous shingles episode does not remove the recommendation for vaccination, but the vaccine should not be given during an active episode. The agency sets no fixed waiting period after shingles once the acute illness has resolved.

The same guidance says a person who receives the second dose later than six months after the first should receive it as soon as possible without restarting the series. That is a US recommendation, not a worldwide rule; a vaccinator should apply the schedule and product label in the country where the dose is given.

Immune suppression, pregnancy and current illness need separate checks

US CDC clinical guidance says vaccination should occur before immunosuppression when possible, or at a time when the immune response is likely to be strongest if treatment has already begun. Disease stability, planned chemotherapy, transplantation and immune-suppressing medicines can change the timing, so the clinician managing that condition needs to be involved.

Recombinant vaccine is not live, which permits its use in many immunocompromised adults under national guidance. That does not make timing interchangeable across conditions, and it does not mean a live shingles vaccine is suitable for the same group.

The US CDC advises postponing recombinant shingles vaccination during pregnancy, an active shingles episode, or a moderate or severe acute illness. A severe allergic reaction to a previous dose or a vaccine component is a contraindication. Routine older-adult recommendations do not apply to children, and eligibility during pregnancy, breastfeeding or adolescence must follow local clinical and regulatory guidance.

Most reported reactions last two or three days

The EMA lists pain, redness and swelling at the injection site among the most common reactions; chills, fever, muscle pain, fatigue, headache, nausea, vomiting, diarrhea and stomach pain may also occur. Most resolve within two or three days.

These expected reactions can interrupt normal activity for a short period, but they do not predict how much protection the vaccine will provide. Persistent, worsening or otherwise concerning symptoms need clinical assessment rather than an assumption that every symptom is vaccine-related.

The US Food and Drug Administration's February 2026 prescribing information warns of an increased risk of Guillain-Barré syndrome (GBS) during the 42 days after recombinant zoster vaccination. Two observational studies of Medicare beneficiaries aged 65 or older estimated three and seven excess GBS cases per million doses in their all-dose analyses. Those estimates are specific to older US populations and do not establish the rate in younger adults or other health systems.

The US CDC vaccine statement lists hives, swelling of the face or throat, difficulty breathing, a fast heartbeat, dizziness and weakness as signs of a possible severe allergic reaction. Those signs require immediate help through the emergency service where the person is located.

Price and public coverage have to be checked locally

WHO asks countries to consider affordability and cost-effectiveness when deciding whether to introduce a shingles vaccination program. That approach produces different age bands, subsidy rules and delivery sites even when countries authorize the same vaccine.

APPI News could not verify vaccine prices, stock or public coverage market by market at the time of writing. The relevant checks are the current national immunization schedule, local product authorization, the public payer or insurer's eligibility rules, and availability from an authorized vaccination provider.

Common questions

Does a past case of shingles remove the need for vaccination?
No under current US CDC guidance. Vaccination can reduce the risk of another episode, but it is postponed during active shingles and the timing must follow local guidance.

Does forgetting a childhood case of chickenpox rule out vaccination?
Not automatically. WHO allows national programs to offer shingles vaccination regardless of reported chickenpox history, while testing and eligibility rules can differ for immunocompromised people and across countries.

Does a delayed second dose mean the course must restart?
Not under the US CDC schedule, which calls for the late second dose without restarting the series. Other countries may use their own product instructions and program rules.

Can every adult choose between live and recombinant vaccines?
No. Product authorization and availability vary by country, the live vaccine is unavailable in the United States, and immune status can rule out a live vaccine even where one remains authorized.

Can the vaccine treat a current shingles rash?
No. Vaccination is preventive, while suspected shingles needs timely clinical assessment; a rash near the eye is a medical emergency.